Clinical trials: Atrial Fibrillation (Prevention of Stroke)
Non Valvular Atrial Fibrillation
LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial Fibrillation
Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds…
- Trial name
- LAmbre2 (NCT07455539)
- Testing
- LAmbre II Left Atrial Appendage Occluder
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Atrial Fibrillation (Prevention of Stroke)
Real-Life Evidence on Stroke Prevention in SPAF
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
- Trial name
- RELIEF (NCT02485873)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists
- Where
- Germany
- Volunteers
- 8,607 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke
Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea
The current study aims to assess the quality of anticoagulation with warfarin in real world practice of secondary stroke prevention in Korean patients with Atrial fibrillation (AF) and to explore predictors for poor International…
- Trial name
- NCT02810509
- Where
- 18 sites in South Korea
- Volunteers
- 1,814 people
- Sponsor
- Inje University
Atrial Fibrillation, Stroke
Electronic Alerts for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, five options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for…
- Trial name
- NCT02958943
- Testing
- On-screen electronic alert
- Where
- United States
- Volunteers
- 798 people
- Sponsor
- Brigham and Women's Hospital
Non-valvular Atrial Fibrillation
Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation
The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism, namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese clinical practice.
- Trial name
- EXPAND (NCT02147444)
- Where
- Japan
- Volunteers
- 7,000 people
- Sponsor
- Tohoku University
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03568916
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 227,579 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Atrial Fibrillation, Stroke
Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II
STROKESTOP II will study if the biomarker NT-proBNP together with single-lead ECG can be used as a primary population screening tool for silent atrial fibrillation, and builds on previous results from the STROKESTOP study.
- Trial name
- STROKESTOP II (NCT02743416)
- Testing
- ECG screening (Zenicor-ECG) for atrial fibrillation
- Where
- Sweden
- Volunteers
- 6,868 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke
Canadian Community Utilization of Stroke Prevention Study - Emergency Department
Atrial fibrillation (AF) is a common heart condition, and increases the risk of stroke by six times. There are several medications (blood thinners) that can prevent strokes in AF patients.
- Trial name
- C-CUSP ED (NCT02358655)
- Testing
- Retrospective review of OAC prescription, Prescription of OAC in ED, Community AF clinic
- Where
- 5 sites in Canada
- Volunteers
- 360 people
- Sponsor
- Population Health Research Institute
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Atrial Fibrillation
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international…
- Trial name
- BOREALIS-AF (NCT00580216)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 538 sites in United States, Argentina and 46 more
- Volunteers
- 3,773 people
- Sponsor
- Sanofi
Atrial Fibrillation, Stroke
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial
EAST prospectively tests the hypothesis that an early, structured rhythm control therapy based on antiarrhythmic drugs and catheter ablation can prevent atrial fibrillation (AF) related complications in patients with AF when…
- Trial name
- EAST (NCT01288352)
- Testing
- early standardised rhythm control
- Where
- 11 sites in Belgium, Czechia and 9 more
- Volunteers
- 2,789 people
- Sponsor
- Atrial Fibrillation Network
Atrial Fibrillation
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population
- Trial name
- NCT00448214
- Testing
- YM150, warfarin
- Where
- 18 sites in Australia, Hong Kong and 8 more
- Volunteers
- 448 people
- Sponsor
- Astellas Pharma Inc
Sinus Rhythm, Atrial Fibrillation
Prevention of Stroke and Sudden Cardiac Death by Recording of 1-Channel Electrocardiograms
Single-channel electrocardiograms (lead I of 12-lead surface ECG; 30 seconds) will be collected from subjects/patients at 11 clinical centers in Germany to train an Artificial Intelligence in the automatic diagnosis of regular…
- Conditions
- Sinus Rhythm, Atrial Fibrillation, Atrial Premature Complexes, Ventricular Premature Complexes
- Trial name
- PRICE (NCT04637230)
- Testing
- Electrocardiogram analysis by Artificial Intelligence
- Where
- Germany
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- A-Rhythmik GmbH
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Atrial Fibrillation, Chronic Kidney Disease
Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease
In this study, the investigators examine whether aspirin or warfarin is useful for atrial fibrillation patients with chronic kidney disease.
- Trial name
- NCT01668901
- Testing
- warfarin, Aspirin
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Atrial Fibrillation
Hong Kong Outpatient AF Screening Using Single-lead ECG Device
Stroke is a leading cause of mortality, morbidity and rising healthcare cost worldwide. In 'real-world' practice, AF is often diagnosed too late at time of stroke and detection can be difficult because AF may be present without…
- Trial name
- NCT02409654
- Testing
- Patient education, Routine care
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Persistent Atrial Fibrillation
Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation: A Safety and Feasibility Study
Atrial fibrillation (AF) affects as many as 1 in 16 people over the age of 65 and reduces the quality of life of large numbers of people in the UK and around the world.
- Trial name
- LEIO-AF (NCT02028130)
- Testing
- LAA electrical isolation + occlusion
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cryptogenic Stroke, Atrial Fibrillation
Stroke of Unknown Cause in Women: The Impact of Long-term Heart Monitoring on Stroke Recurrence
The goal of this observational study is to investigate sex - differences in detection rate of atrial fibrillation after cryptogenic stroke (embolic stroke of unknown cause) - using an implantable cardiac rhythm monitor - and the…
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Implantable Cardiac Monitor, Secondary Stroke Prevention
- Trial name
- STROKEWISE (NCT07194811)
- Where
- Norway
- Volunteers
- 1,400 people
- Sponsor
- University Hospital, Akershus